{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:42:13Z","timestamp":1696570933408},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T00:00:00Z","timestamp":1399593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"DFG-SU122\/3-1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:label \/><jats:p>Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low\u2010level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re\u2010introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects. Pediatr Blood Cancer 2014;61:2080\u20132082. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.25090","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T05:07:10Z","timestamp":1399612030000},"page":"2080-2082","source":"Crossref","is-referenced-by-count":9,"title":["Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia"],"prefix":"10.1002","volume":"61","author":[{"given":"Olga","family":"Moser","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology University Hospital Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Krumbholz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Pediatric Hematology and Oncology University Hospital Erlangen Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital \u201cCarl Gustav Carus\u201d Technical University Dresden Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine T.","family":"Tauer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Pediatric Hematology and Oncology University Hospital \u201cCarl Gustav Carus\u201d Technical University Dresden Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indra","family":"Janz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Pediatric Hematology and Oncology University Hospital Schleswig\u2010Holstein Campus L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melchior","family":"Lauten","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Pediatric Hematology and Oncology University Hospital Schleswig\u2010Holstein Campus L\u00fcbeck L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Dilloo","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology University Hospital Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Pediatric Hematology and Oncology University Hospital Erlangen Erlangen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Pediatric Hematology and Oncology University Hospital \u201cCarl Gustav Carus\u201d Technical University Dresden Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.02.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12977"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.368"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7114"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.883599"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24521"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.21989"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.185"},{"key":"e_1_2_6_12_1","first-page":"402","article-title":"The majority of chronic myeloid leukemia patients who cease imatinib after achieving a sustained complete molecular remission (CMR) remain in CMR, and any relapses occur early","volume":"112","author":"Ross DM","year":"2008","journal-title":"Blood"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.009134"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162388"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.196477"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237404"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24397"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.03.046"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1343483"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067447"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1182\/blood.V120.21.3752.3752","article-title":"Impact of treatment with tyrosine kinase inhibitors (TKIs) on blood levels of growth hormone, testosterone, and inhibin B in juvenile rats and pediatric patients with chronic myeloid leukemia","volume":"120","author":"Ulmer A","year":"2012","journal-title":"Blood"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25090","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.25090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T04:21:52Z","timestamp":1696479712000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,9]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/pbc.25090"],"URL":"https:\/\/doi.org\/10.1002\/pbc.25090","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,9]]}}}